Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Epstein-Barr virus gp350-ferritin nanoparticle vaccine with saponin-based adjuvant

A ferritin-based, nanoparticle vaccine consisting of the Epstein-Barr Virus (EBV) envelop glycoprotein gp350 and a saponin-based adjuvant, with potential immunizing activity against EBV. Upon intramuscular administration of EBV gp350-ferritin nanoparticle vaccine with saponin-based adjuvant, the EBV gp350 may activate both humoral and cellular immune responses which may result in protection against EBV infection. EBV, a ubiquitous human herpes virus, is associated with infectious mononucleosis and various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:EBV gp350-based nanoparticle vaccine
EBV gp350-based nanoparticles vaccine
EBV gp350-ferritin nanoparticle vaccine with saponin-based adjuvant
EBV gp350-ferritin vaccine
EBV gp350-ferritin vaccine/matrix M1
Epstein-Barr virus gp350-ferritin nanoparticle vaccine with matrix-M1 adjuvant
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search